Prothena Corp PLC PRTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PRTA is a good fit for your portfolio.
News
-
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
-
Prothena to Participate in Upcoming Healthcare Conferences
-
Prothena Appoints David Ford to Newly Created Chief People Officer Position
-
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
-
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
-
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
Trading Information
- Previous Close Price
- $21.29
- Day Range
- $20.44–21.70
- 52-Week Range
- $20.42–79.65
- Bid/Ask
- $20.00 / $20.88
- Market Cap
- $1.10 Bil
- Volume/Avg
- 442,898 / 644,167
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.97
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 173
- Website
- https://www.prothena.com
Comparables
Valuation
|
Metric
|
PRTA
|
GHRS
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.97 | 2.70 | 12.65 |
Price/Sales | 11.97 | — | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
PRTA
GHRS
CBAY
Financial Strength
|
Metric
|
PRTA
|
GHRS
|
CBAY
|
|---|---|---|---|
Quick Ratio | 10.97 | 24.14 | 10.70 |
Current Ratio | 11.24 | 24.49 | 10.96 |
Interest Coverage | — | −706.38 | −5.27 |
Quick Ratio
PRTA
GHRS
CBAY
Profitability
|
Metric
|
PRTA
|
GHRS
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −14.95% | −12.75% | −30.06% |
Return on Equity (Normalized) | −18.32% | −13.12% | −51.97% |
Return on Invested Capital (Normalized) | −22.78% | −16.87% | −30.87% |
Return on Assets
PRTA
GHRS
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wdscctmdkr | Mhgz | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rffhhtw | Qjblhy | $104.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kbkvhcz | Pblrk | $98.8 Bil | |
MRNA
| Moderna Inc | Yqcfpssk | Sgkp | $38.8 Bil | |
ARGX
| argenx SE ADR | Wyvxljv | Rth | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Krbwfyhph | Hytf | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ftwrckjn | Vdrhbq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Svmzwmqx | Lwvjfn | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rqqbvdlfqz | Cfxwhv | $12.4 Bil | |
INCY
| Incyte Corp | Yvgpwgqk | Tsynkg | $11.9 Bil |